abelheira schreef op 16 februari 2017 14:59:
Pfizer's Xeljanz + methotrexate matches Humira + methotrexate but falls short as monotherapy in RA study :
•Results from a Phase 3b/4 clinical trial, ORAL Strategy, assessing Pfizer's (NYSE:PFE) XELJANZ (tofacitinib) plus methotrexate (MTX) compared to AbbVie's (NYSE:ABBV) Humira (adalimumab) plus MTX in patients with moderate-to-severe rheumatoid arthritis (RA) showed the XELJANZ therapy to be non-inferior (no worse than) to the Humira therapy, one of the primary endpoints, as measured by ACR50 (50% improvement in RA symptoms) at month 6.
•XELJANZ as monotherapy failed to demonstrate non-inferiority versus either of the combination therapies, another primary endpoint.
•The study was the first to compare a JAK inhibitor, with and without MTX, to Humira.
•Complete data will be presenting at an upcoming scientific meeting.